Bristol Myers Reaches $239 Million Settlement Over Psoriasis, MS Drugs
Insurance Journal - Nov 07, 2025
Bristol Myers Squibb reached a $239 million settlement of claims that former Celgene shareholders were defrauded about prospects for the psoriasis drug Otezla, and multiple sclerosis treatment now known as Zeposia. A preliminary settlement of the 7-1/2-year-old class action was …...
Recommended Articles
Posted: Nov 07, 2025
An explosion at a hydrogen and nitrogen product manufacturer in Mississippi on Wednesday caused an a...
Posted: Nov 07, 2025
AM Best has placed under review with positive implications the Financial Strength Rating of B++ (Goo...
Posted: Nov 07, 2025
A former South Carolina state lawmaker and injury lawyer has been indicted on federal allegations th...